Health-related quality of life in patients with autoimmune hepatitis.
AIH
Biochemical remission
CLDQ
EQ-5D-5L
HRQL
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
accepted:
16
04
2021
pubmed:
13
5
2021
medline:
26
11
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
Autoimmune hepatitis (AIH) is a rare chronic liver disease. Impaired health-related quality of life (HRQL) contributes to the overall disease burden. At current, only limited data related to the impact of treatment response on HRQL are available. The aim of the study was to determine the impact of biochemical remission on HRQL. Patients with AIH were prospectively enrolled between July 2018 and June 2019. A liver disease-specific tool, the chronic liver disease questionnaire (CLDQ) and the generic EQ-5D-5L were used to quantify HRQL. Treatment response was assessed biochemically by measurement of immunoglobulin G, ALT and AST. The cohort was divided into two groups according to their biochemical remission status in either complete vs. incomplete remission. Clinical as well as laboratory parameters and comorbidities were analysed using univariable and multivariable analysis to identify predictors of poor HRQL. A total of 116 AIH patients were included (median age: 55; 77.6% female), of which 9.5% had liver cirrhosis. In this cohort, 38 (38.4%) showed a complete and 61 (61.6%) an incomplete biochemical remission at study entry. The HRQL was significantly higher in patients with a complete as compared to an incomplete biochemical remission (CLDQ overall score: 5.66 ± 1.15 vs. 5.10 ± 1.35; p = 0.03). In contrast, the generic EQ-5D-5L UI-value was not different between the groups. Multivariable analysis identified AST (p = 0.02) and an incomplete biochemical remission (p = 0.04) as independent predictors of reduced HRQL (CLDQ total value). Patients with a complete biochemical remission had a significantly higher HRQL. Liver-related quality of life in patients living with AIH is dependent on the response to immunosuppressive treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Autoimmune hepatitis (AIH) is a rare chronic liver disease. Impaired health-related quality of life (HRQL) contributes to the overall disease burden. At current, only limited data related to the impact of treatment response on HRQL are available.
OBJECTIVE
OBJECTIVE
The aim of the study was to determine the impact of biochemical remission on HRQL.
METHODS
METHODS
Patients with AIH were prospectively enrolled between July 2018 and June 2019. A liver disease-specific tool, the chronic liver disease questionnaire (CLDQ) and the generic EQ-5D-5L were used to quantify HRQL. Treatment response was assessed biochemically by measurement of immunoglobulin G, ALT and AST. The cohort was divided into two groups according to their biochemical remission status in either complete vs. incomplete remission. Clinical as well as laboratory parameters and comorbidities were analysed using univariable and multivariable analysis to identify predictors of poor HRQL.
RESULTS
RESULTS
A total of 116 AIH patients were included (median age: 55; 77.6% female), of which 9.5% had liver cirrhosis. In this cohort, 38 (38.4%) showed a complete and 61 (61.6%) an incomplete biochemical remission at study entry. The HRQL was significantly higher in patients with a complete as compared to an incomplete biochemical remission (CLDQ overall score: 5.66 ± 1.15 vs. 5.10 ± 1.35; p = 0.03). In contrast, the generic EQ-5D-5L UI-value was not different between the groups. Multivariable analysis identified AST (p = 0.02) and an incomplete biochemical remission (p = 0.04) as independent predictors of reduced HRQL (CLDQ total value).
CONCLUSION
CONCLUSIONS
Patients with a complete biochemical remission had a significantly higher HRQL. Liver-related quality of life in patients living with AIH is dependent on the response to immunosuppressive treatment.
Identifiants
pubmed: 33978892
doi: 10.1007/s11136-021-02850-0
pii: 10.1007/s11136-021-02850-0
pmc: PMC8481193
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2853-2861Informations de copyright
© 2021. The Author(s).
Références
Feld, J. J., & Heathcote, E. J. (2003). Epidemiology of autoimmune liver disease. Journal of Gastroenterology and Hepatology, 18, 1118–1128
doi: 10.1046/j.1440-1746.2003.03165.x
Krawitt, E. L. (2006). Autoimmune hepatitis. New England Journal of Medicine, 354, 54–66
doi: 10.1056/NEJMra050408
van Gerven, N. M. F., Verwer, B. J., Witte, B. I., van Erpecum, K. J., van Buuren, H. R., Maijers, I., Visscher, A. P., Verschuren, E. C., van Hoek, B., Coenraad, M. J., & Beuers, U. H. (2014). Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scandinavian Journal of Gastroenterology, 49, 1245–1254
doi: 10.3109/00365521.2014.946083
Lamers, M. M. H., van Oijen, M. G. H., Pronk, M., & Drenth, J. P. (2010). Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials. Journal of Hepatology, 53, 191–198
doi: 10.1016/j.jhep.2010.01.037
Schramm, C. (2019). Autoimmune hepatitis beyond steroids: Effective trial design and attention to quality of life. Clinical Liver Disease (Hoboken), 14, 33–36
doi: 10.1002/cld.816
Sebode, M., Hartl, J., Vergani, D., Lohse, A. W., & International Autoimmune Hepatitis Group (IAIHG). (2018). Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver International, 38, 15–22
doi: 10.1111/liv.13458
Hoeroldt, B., McFarlane, E., Dube, A., Basumani, P., Karajeh, M., Campbell, M. J., & Gleeson, D. (2011). Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology, 140, 1980–1989
doi: 10.1053/j.gastro.2011.02.065
EASL Clinical Practice Guidelines. (2015). Autoimmune hepatitis. Journal of Hepatology, 63, 971–1004
doi: 10.1016/j.jhep.2015.06.030
Mack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2019). Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology, 72, 671–722
doi: 10.1002/hep.31065
Schramm, C., Wahl, I., Weiler-Normann, C., Voigt, K., Wiegard, C., Glaubke, C., Brähler, E., Löwe, B., Lohse, A. W., & Rose, M. (2014). Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. Journal of Hepatology, 60, 618–624
doi: 10.1016/j.jhep.2013.10.035
Sockalingam, S., Blank, D., Abdelhamid, N., Abbey, S. E., & Hirschfield, G. M. (2012). Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors. Journal of Hepatology, 57, 1299–1304
doi: 10.1016/j.jhep.2012.07.032
Wong, L. L., Fisher, H. F., Stocken, D. D., Rice, S., Khanna, A., Heneghan, M. A., Oo, Y. H., Mells, G., Kendrick, S., Dyson, J. K., & Jones, D. E. (2018). The impact of autoimmune hepatitis and its treatment on health utility. Hepatology, 68, 1487–1497
doi: 10.1002/hep.30031
Takahashi, A., Moriya, K., Ohira, H., Arinaga-Hino, T., Zeniya, M., Torimura, T., Abe, M., Takaki, A., Kang, J. H., Inui, A., & Fujisawa, T. (2018). Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS One, 13, e0204772
doi: 10.1371/journal.pone.0204772
Janik, M. K., Wunsch, E., Raszeja-Wyszomirska, J., Moskwa, M., Kruk, B., Krawczyk, M., & Milkiewicz, P. (2019). Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver International, 39, 215–221
doi: 10.1111/liv.13960
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010). Diagnosis and management of autoimmune hepatitis. Hepatology, 51, 2193–2213
doi: 10.1002/hep.23584
Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45, 295–300
doi: 10.1136/gut.45.2.295
Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11, 275–284
doi: 10.1111/j.1524-4733.2007.00230.x
Ludwig, K., Graf von der Schulenburg, J.-M., & Greiner, W. (2018). German value set for the EQ-5D-5L. Pharmacoeconomics, 36, 663–674
doi: 10.1007/s40273-018-0615-8
Labenz, C., Toenges, G., Schattenberg, J. M., Nagel, M., Sprinzl, M. F., Nguyen-Tat, M., Zimmermann, T., Huber, Y., Marquardt, J. U., Galle, P. R., & Wörns, M. A. (2019). Clinical predictors for poor quality of life in patients with covert hepatic encephalopathy. Journal of Clinical Gastroenterology, 53, e303–e307
doi: 10.1097/MCG.0000000000001149
van der Plas, S. M., Hansen, B. E., de Boer, J. B., Stijnen, T., Passchier, J., Rob, A., & Schalm, S. W. (2007). Generic and disease-specific health related quality of life of liver patients with various aetiologies: A survey. Quality of Life Research, 16, 375–388
doi: 10.1007/s11136-006-9131-y
Huber, Y., Boyle, M., Hallsworth, K., Tiniakos, D., Straub, B. K., Labenz, C., Ruckes, C., Galle, P. R., Romero-Gómez, M., Anstee, Q. M., & Schattenberg, J. M. (2019). Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clinical Gastroenterology and Hepatology, 17, 2085–2092.e1
doi: 10.1016/j.cgh.2018.12.016
Dyson, J. K., de Martin, E., Dalekos, G. N., Drenth, J. P., Herkel, J., Hubscher, S. G., Kelly, D., Lenzi, M., Milkiewicz, P., Oo, Y. H., & Heneghan, M. A. (2019). Review article: Unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Alimentary Pharmacology & Therapeutics, 49, 528–536
doi: 10.1111/apt.15111
Montali, L., Frigerio, A., Riva, P., & Invernizzi, P. (2011). ‘It’s as if PBC didn’t exist’: The illness experience of women affected by primary biliary cirrhosis. Psychology & Health, 26, 1429–1445
doi: 10.1080/08870446.2011.565876
Sahebjam, F., & Vierling, J. M. (2015). Autoimmune hepatitis. Frontiers in Medicine, 9, 187–219
doi: 10.1007/s11684-015-0386-y
Al-Chalabi, T., Underhill, J. A., Portmann, B. C., McFarlane, I. G., & Heneghan, M. A. (2008). Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clinical Gastroenterology and Hepatology, 6, 1389–1395
doi: 10.1016/j.cgh.2008.08.018
Orr, J. G., Homer, T., Ternent, L., Newton, J., McNeil, C. J., Hudson, M., & Jones, D. E. (2014). Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology, 61, 1158–1165
doi: 10.1016/j.jhep.2014.06.034